← Back to screener

TransMedics Group, Inc. TMDX

Rank #2347 · Nasdaq · $2.3B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
23.0
P/E
-91.1
P/B
12.17
ROE
-13.4%
Op. Margin
-11.9%
Debt Ratio
307%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -91.1x, P/B 12.17x. Ranks in the top 76% of the universe.

Profitability ★☆☆☆☆
Weak

ROE -13.4%. Ranks in the top 78% of the universe.

Safety ★☆☆☆☆
Weak

Debt ratio 307%. Ranks in the top 72% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★★
Excellent

Revenue growth of 158.5% year over year. Ranks in the top 2% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2019$0.0B$-0.0B$-0.0B$-0.2B-155.5-28
2020$0.0B$-0.0B$-0.0B$-0.2B-125.4-26
2021$0.0B$-0.0B$-0.0B$0.1B-102.988
2022$0.0B$-0.0B$-0.0B$0.1B-102.9123
2023$0.0B$-0.0B$-0.0B$0.1B-130.386
2024$0.1B$-0.0B$-0.0B$0.1B-33.6838
2025$0.2B$-0.0B$-0.0B$0.2B-11.9307

← See the full screener